Stimulates insulin release from functioning beta cells in the pancreas; may improve
binding between insulin and insulin receptors or increase the number of insulin receptors;
more potent in effect than first-generation sulfonylureas.
Adjunct to insulin therapy in the stabilization of certain cases of type 2 diabetes,
reducing the insulin requirement, and decreasing the chance of hypoglycemic
Contraindicated with allergy to sulfonylureas; diabetes with ketoacidosis, sole
therapy of type 1 (insulin-dependent) diabetes or diabetes complicated by
pregnancy, serious hepatic or renal impairment, uremia; diabetes complicated by
fever, severe infections, severe trauma, major surgery, ketosis, acidosis, coma
(insulin is contraindicated); thyroid or endocrine impairment, glycosuria,
hyperglycemia associated with primary renal disease; labor and delivery (if
glyburide is used during pregnancy, discontinue drug at least 1 mo before
Geriatric patients tend to be more sensitive to the drug; start with initial dose of
1.25 mg/day PO (DiaBeta, Micronase) 0.75 mg/day PO (Glynase). Monitor for 24 hr, and
gradually increase dose after at least 1 wk as needed.
Metabolism: Hepatic; T1/2: 4 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Bile and urine
Now bringing you back...
Does that email address look wrong? Try again with a different email.